Naland Shenoy, MD
Endocrinology, Diabetes & Metabolism · Snellville, GANPI 1972598852
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $114,866 of the $139,261 with a category attached, or 82.5%. 49 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 43.7% of the total. Reporting peaked in 2019 at $75,003 and has fallen 98.2% since, to $1,351 in 2025. Among endocrinology, diabetes & metabolism clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 923 payments — averaging $150.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$61K
- Lilly USA, LLC$50K
- AstraZeneca$19K
- Novo Nordisk$1K
- Corcept Therapeutics$716
- Mannkind Corporation$646
- plus $7K from 43 others
What the payments were for
- Consulting fees$2,6002%
- Speaking & faculty fees$114,86682%
- Travel & lodging$7,1285%
- Food & beverage$14,58510%
- Education$810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SOLIQUA 100/33$44,673
- HUMULIN$30,098
- TOUJEO$22,447
- FARXIGA$18,250
- BAQSIMI$12,606
- TRULICITY$1,796
- CeQur Simplicity$546
- TZIELD$141
How this compares
$139,261 in reported general payments places this provider in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 12 | $516,285 |
| OzempicSemaglutide | 306 | $494,523 |
| TrulicityDulaglutide | 129 | $217,661 |
| MounjaroTirzepatide | 68 | $143,505 |
| FarxigaDapagliflozin Propanediol | 110 | $141,919 |
| Tresiba Flextouch U-100Insulin Degludec | 117 | $115,016 |
| JardianceEmpagliflozin | 91 | $112,283 |
| JanuviaSitagliptin Phosphate | 77 | $89,646 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 73 | $77,723 |
| AfrezzaInsulin Regular, Human | 25 | $64,365 |
| ProliaDenosumab | 32 | $54,679 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $46,001 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 31 | $43,681 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 18 | $36,564 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 168 | $31,567 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,143 | $526,704346 claims |
| Corcept TherapeuticsKorlym | $716 | $516,28512 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $50,032 | $383,028252 claims |
| AstraZenecaFarxiga | $19,430 | $141,919110 claims |
| Boehringer IngelheimJardiance | $404 | $112,28391 claims |
| MerckJanuvia, Janumet Xr | $303 | $106,31488 claims |
| Mannkind CorporationAfrezza | $646 | $64,36525 claims |
| AmgenProlia | $525 | $54,67932 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $60,790 | $34,59251 claims |
| Cequr CorporationCequr Simplicity | $574 | $15,33626 claims |
| Johnson & JohnsonInvokana | $44 | $15,07516 claims |
| AbbVieSynthroid | $390 | $15,067151 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Snellville
- Sayed AamirSnellville$9K
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Adeniyi OdugbesanLawrenceville$636K
- Miguel MunozMarietta$476K
- Jason BernerJasper$457K
- Dawn Smiley-ByrdTaylorsville$385K
- Barry JohnsMacon$335K
- Jonathan OwnbyAtlanta$291K
- Ismary DecastroSavannah$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.